Newm-035 Here

The drug was developed by , a spinoff from Kyoto University, led by Dr. Katsu Takahashi.

: Success in Phase I will lead to trials for children aged 2–7 with congenital anodontia (being born without a full set of teeth). Future Outlook NEWM-035

: The treatment is administered via an intravenous injection . By neutralizing USAG-1, the drug reactivates these dormant buds, allowing the body to use its natural BMP and Wnt signaling pathways to form new, functional teeth. Clinical Development and Trials The drug was developed by , a spinoff